We all know the U.S. government is in debt up to its eyeballs. Moody’s is already threatening to downgrade the country’s debt rating due to unfunded liabilities for Medicare and Social Security.

The media have dubbed it “the new age of epidemics.” From SARS to cancer, diabetes to the flu, we live in a world of increasingly powerful germs and diseases.

As times change, so do trends. In the old days, the louder and more powerful your car, the better. Now, green is the name of the game and everyone wants to drive super quiet, efficient hybrids.

Everyone knows markets hate uncertainty. Nowhere is that borne out more than in biotech.

In 2002, Alkermes thought it had a winner on its hands… The small biotech and its Big Pharma partner, Johnson & Johnson, had developed the drug Risperdal Consta to combat schizophrenia. It was a great deal for a while… The market assumed the drug would be approved by the FDA the first time around.